WASHINGTON (Reuters)—U.S. Supreme Court justices on Wednesday struggled over whether to speed up the time it takes to bring to the market copycat versions of biologic drugs, expensive medicines that can generate billions of dollars in sales for drug makers. The nine justices heard arguments in an appeal by Novartis AG of a lower court…
Search results for: drug prices
The ACR Agenda in D.C.: Where We Stand in Mid-April
Editor’s note: This blog by Dr. Worthing originally appeared on the ACR’s Advocacy Listserv. Here’s a perspective on the current climate in which your government affairs team works. As you read this list of observations, imagine you’re a lawmaker and try to find where the ACR’s agenda fits into the current landscape: Washington is highly…
AHCA, ACR Health Policy & More
Editor’s note: This blog by Dr. Worthing originally appeared on the ACR’s Advocacy Listserv. What a month! House Republicans introduced their bill to repeal and replace Obamacare. The ACR has analyzed the bill and believes the American Health Care Act (AHCA) does not go far enough to help Americans with rheumatic diseases. Brief recap: The…
OIG Releases 2017 Work Plan: A Summary
Each fall, the Department of Health and Human Services (HHS) Office of Inspector General (OIG) puts out its Work Plan for the upcoming fiscal year to summarize its initiatives and priorities for new and ongoing work of HSS programs. Below is a summary of the key areas the OIG will focus on in 2017: Drug…
The ACR Government Affairs Committee’s Outgoing Chair Urges Members to Continue Advocating for Rheumatology
WASHINGTON, D.C.—Although political polarization in the U.S. has affected many people’s interest in participating in legislative and advocacy efforts that promote their concerns, William Harvey, MD, MSc, the ACR’s (immediate past) chair of the Government Affairs Committee, encouraged rheumatologists and ACR/ARHP members to remain engaged and get involved with the ACR to fight for issues…
U.S. Appeals Court: Hospitals Can Be ‘Urban’ & ‘Rural’ at Same Time
NEW YORK (Reuters)—The federal appeals court in New York struck down a U.S. regulation that made it harder for hospitals to provide better medical care at lower cost by claiming they were “rural” for some purposes and “urban” for others. Thursday’s decision by the Second U.S. Circuit Court of Appeals is a victory for hospitals…
Annual Meeting Advocacy Recap
Advocacy was front and center at the 2015 ACR/ARHP Annual Meeting, and in case you missed something, Will Harvey, MD, provides a summary here…
Biotechs Extend Selloff as Pricing Concerns Intensify
NEW YORK (Reuters)—U.S. biotech shares extended their recent downward spiral on Tuesday as concerns about drug pricing continued to plague the sector while disappointing news from Illumina and other companies added to selling pressure. The Nasdaq Biotechnology index, down 4%, has now fallen about 17% since just before Hillary Clinton, front-runner to be the Democratic nominee…
U.S. Predicts 5.8% Average Rise in Healthcare Spending Through 2024
NEW YORK (Reuters)—The U.S. government expects healthcare spending to increase by 5.8% annually on average from 2014 through 2024 as more Americans gain insurance coverage and the improved economy drives patients to visit doctors and hospitals. The aging population’s higher healthcare costs will also push health spending higher starting in 2019, according to a study…
Rising Costs of Biologics in the U.S. Suggest Need for Negotiation Ability
The costs of some disease-modifying therapies outpace prescription drug inflation, saddling insured patients with thousands of dollars in out-of-pocket payments and delayed or denied coverage, two new studies have shown. Disease-modifying therapies for multiple sclerosis are rising in cost five to seven times faster than inflation and cost more in the United States than in…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 25
- Next Page »